HDL re-examined

Current Opinion in Lipidology

Volumn 26, Issue 2, 2015, Pages 127-132

  Hovingh, G Kees ^a   Rader, Daniel J ^b   Hegele, Robert A ^c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

cardiovascular disease; cholesterol efflux; HDL C

Indexed keywords

APOLIPOPROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TORCETRAPIB; AGENTS AFFECTING LIPID METABOLISM;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; EPIDEMIOLOGICAL DATA; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; LOSS OF FUNCTION MUTATION; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; GENETICS; LIPID METABOLISM; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLINICAL TRIALS AS TOPIC; HUMANS; LIPID METABOLISM; LIPID REGULATING AGENTS; RISK FACTORS;

EID: 84938936214     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000161     Document Type: Review

References (62)

1. Kannel WB, Dawber TR, Friedman GD, et al. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; the Framingham study. Ann Intern Med 1964; 61:888-899.
2. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85:1234-1243.
3. Rubin E, Krauss R, Spangler E, et al. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991; 353:265-267.
4. Glomset JA, Janssen ET, Kennedy R, Dobbins J. Role of plasma lecithin: cholesterol acyltransferase in the metabolism of high density lipoproteins. J Lipid Res 1966; 7:638-648.
5. van der Steeg WA, Holme I, Boekholdt SM, et al. High-Density lipoprotein cholesterol, high-Density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008; 51:634-642.
6. Yeh PS, Yang CM, Lin SH, et al. Low levels of high-Density lipoprotein cholesterol in patients with atherosclerotic stroke: a prospective cohort study. Atherosclerosis 2013; 228:472-477.
7. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285:2481-2485.
8. Ray KK, Kastelein JJ, Boekholdt SM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014; 35:960-968.
9. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 2014; 129 (Suppl 2):S49-S73.
10. Olsson AG, Schwartz GG, Szarek M, et al. High-Density lipoprotein, but not low-Density lipoprotein cholesterol levels influence short-Term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005; 26:890-896.
11. Ray KK, Cannon CP, Cairns R, et al. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol 2009; 29:424-430.
12. Boekholdt SM, Arsenault BJ, Hovingh GK, et al. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-Treated patients: a meta-Analysis. Circulation 2013; 128:1504-1512.
13. Emerging Risk Factors Collaboration. Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and cardiovascular disease prediction. JAMA 2012; 307:2499-2506.
14. Mora S, Buring JE, Ridker PM, Cui Y. Association of high-Density lipoprotein cholesterol with incident cardiovascular events in women, by low-Density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study. Ann Intern Med 2011; 155:742-750.
15. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-Density lipoprotein in subjects with isolated low high-Density lipoprotein. Circulation 2003; 107:2944-2948.
16. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999; 100:594-598.
17. Rye KA, Barter PJ. Cardioprotective functions of HDLs. J Lipid Res 2014; 55:168-179.
18. Funke H, von Eckardstein A, Pritchard PH, et al. A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-Acyltransferase deficiency, and corneal opacities. J Clin Invest 1991; 81:371-376.
19. Kuivenhoven JA, Weibusch H, Pritchard PH, et al. An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish-Eye disease). J Clin Invest 1996; 98:358-364.
20. Candini C, Schimmel AW, Peter J, et al. Identification and characterization of novel loss of function mutations in ATP-binding cassette transporter A1 in patients with low plasma high-Density lipoprotein cholesterol. Atherosclerosis 2010; 213:492-498.
21. Hovingh GK, Brownlie A, Bisoendial RJ, et al. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol 2004; 44:1429-1435.
22. Oldoni F, Sinke RJ, Kuivenhoven JA. Mendelian disorders of high-Density lipoprotein metabolism. Circ Res 2014; 114:124-142.
23. Tietjen I, Hovingh GK, Singaraja R, et al. Increased risk of coro-nary artery disease in Caucasians with extremely low HDL cho-lesterol due to mutations in ABCA1, APOA1, and LCAT. Biochim Biophys Acta 2012; 1821:416-424.
24. Calabresi L, Baldassarre D, Castelnuovo S, et al. Functional leci-thin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 2009; 120:628-635.
25. Hovingh GK, Hutten BA, Holleboom AG, et al. Compromised LCAT function is associated with increased atherosclerosis. Circulation 2005; 112:879-884.
26. Van Dam MJ, De Groot E, Clee SM, et al. Association between increased arterial-wall thickness and impairment in ABCA1-Driven cho-lesterol efflux: an observational study. Lancet 2002; 359:37-42.
27. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-offunction mutations in the ABCA1 gene with high-Density lipoprotein cholesterol levels and risk of ischemic heart disease. JAMA 2008; 299:524-532.
28. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001; 103:1949-1954.
29. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest 2009; 119:1042-1050.
30. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet 2012; 380:572-580.
31. Do R, Willer CJ, Schmidt EM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet 2013; 45:1345-1352.
32. Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014; 371:22-31.
33. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014; 371:32-41.
34. Bernelot Moens SJ, van Capelleveen JC, Stroes ES. Inhibition of ApoCIII: the next PCSK9?. Curr Opin Lipidol 2014; 25:418-422.
35. Johannsen TH, Frikke-Schmidt R, Schou J, et al. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects. J Am Coll Cardiol 2012; 60:2041-2048.
36. Kathiresan S. Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-Density lipoprotein cholesterol?. Insights from human genetics and clinical trials. J Am Coll Cardiol 2012; 60:2049-2052.
37. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008; 101:S20-S26.
38. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long term benefit with niacin. J Am Coll Cardiol 1986; 8:1245-1255.
39. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
40. HPS2-THRIVE Collaborative Group. Landray MJ, Haynes R, Hopewell JC, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014; 371:203-212.
41. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 2013; 61:440-446.
42. Inazu A, Brown ML, Hesler CB, et al. Increased high-Density lipoprotein levels caused by a common cholesteryl-Ester transfer protein gene mutation. N Engl J Med 1990; 323:1234-1238.
43. Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996; 97:2917-2923.
44. Curb JD, Abbott RD, Rodriguez BL, et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 2004; 45:948-953.
45. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002; 105:2159-2165.
46. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.
47. Funder JW. Aldosterone, sodium, and hypertension: lessons from torcetrapib?. Hypertension 2010; 55:221-223.
48. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367:2089-2099.
49. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363:2406-2415.
50. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011; 306:2099-2109.
51. Ford J, Lawson M, Fowler D, et al. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol 2014; 78:498-508.
52. van Capelleveen JC, Brewer HB, Kastelein JJ, Hovingh GK. Novel therapies focused on the high-Density lipoprotein particle. Circ Res 2014; 114:193-204.
53. Tardif JC, Ballantyne CM, Barter P, et al. Effects of the high-Density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 2014; 35:3277-3286.
54. Khera AV, Cuchel M, de la Llera-Moya M, et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364:127-135.
55. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, et al. The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-Density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 2010; 30:796-801.
56. Li XM, Tang WH, Mosior MK, et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013; 33:1696-1705.
57. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014; 371:2383-2393.
58. Ray KK, Ditmarsch M, Kallend D, et al. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J 2014; 35:1792-1800.
59. American Heart Association. American Heart Association Scientific Session Meeting 15-19 November 2014. Chicago, USA. Poster# 2062 presented Nov18 2014. https //aha.apprisor.org/epsAbstractAHA.cfm?id1. [Accessed 11 December, 2014]
60. Rosenson RS, Brewer HB Jr, Ansell B, et al. Translation of high-Density lipoprotein function into clinical practice: current prospects and future challenges. Circulation 2013; 128:1256-1267.
61. Kratzer A, Giral H, Landmesser U. High-Density lipoproteins as modulators of endothelial cell functions: alterations in patients with coronary artery disease. Cardiovasc Res 2014; 103:350-361.
62. Besler C, Heinrich K, Rohrer L, et al. Mechanisms underlying adverse effects of HDL on eNOS-Activating pathways in patients with coronary artery disease. J Clin Invest 2011; 121:2693-2708.